Oncolytics Biotech Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Oncolytics Biotech Inc. (NASDAQ: ONCY; TSX: ONC) is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously administered oncolytic immunotherapy derived from a proprietary reovirus isolate that selectively replicates in cancer cells to induce innate and adaptive immune responses, turning immunologically cold tumors hot by expanding tumor-infiltrating lymphocytes, upregulating interferons, CXCL9/10/11, and PD-L1; pelareorep targets solid tumors and hematological malignancies including HR+/HER2- metastatic breast cancer, pancreatic ductal adenocarcinoma, colorectal cancer, squamous cell carcinoma of the anal canal, and others, demonstrating synergies with standard-of-care therapies such as chemotherapy (gemcitabine/nab-paclitaxel, modified FOLFIRINOX), checkpoint inhibitors (atezolizumab/Tecentriq), and hormonal treatments in ongoing and planned registrational trials like BRACELET-1, GOBLET, and AWARE-1. The company, founded in 1998 and headquartered in Calgary, Alberta, Canada, with key operations in San Diego, California, conducts clinical development across North America and partners with global collaborators including Roche Holding AG for atezolizumab supply, Pfizer Inc., Merck Serono, Incyte Corporation, Adlai Nortye, Mayo Clinic, Duke University, and others to evaluate combination regimens in gastrointestinal, breast, and hematologic cancers; it employs approximately 28 people and lists on NASDAQ and TSX following its 1999 IPO. Recent developments include alignment with the FDA in November 2025 on pivotal study design for pelareorep in first-line pancreatic cancer, establishment of a gastrointestinal tumor scientific advisory board in November 2025 to advance pelareorep as a platform therapy, updated anal cancer data in October 2025 showing objective response rates more than double the standard of care, progress toward full enrollment in the pancreatic cancer study with positive regulatory feedback, expanded U.S. sites for the GOBLET trial, and a April 2025 share purchase agreement with Alumni Capital LP providing up to $20 million in flexible non-dilutive funding over 15 months to support clinical milestones.
Company News
Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep's Potential in Colorectal Cancer
Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update
Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer
Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer
Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044
Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer
Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors
Penny Stock Oncolytics Biotech Says Colorecatal Cancer Drug's Durability Tops Historical Benchmarks
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths
Financial Comparison: Erasca (NASDAQ:ERAS) vs. Oncolytics Biotech (NASDAQ:ONCY)
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Consensus Rating of “Moderate Buy” from Analysts